Eye

Our Eye research team is developing and testing new gene therapy approaches for inherited retinal diseases (IRDs) and age-related macular degeneration (AMD), conditions that can cause progressive sight loss. These diseases affect the retina, the light-sensitive tissue at the back of the eye that converts light into signals sent to the brain.

The team is investigating how genetic therapies could be used to address the underlying causes of retinal disease, with the aim of protecting retinal cells, slowing disease progression and potentially preserving or improving vision. Alongside developing these therapies, researchers are exploring delivery technologies that can transport therapeutic genetic material into the appropriate cells within the eye.

The research is organised around three parallel projects, each contributing to the development of a broader range of gene therapy tools and delivery methods. Together, these approaches aim to establish a flexible platform for developing treatments that could be adapted to different inherited retinal conditions and other diseases affecting vision.

By combining therapeutic development with advances in delivery technology, the team hopes to expand the range of retinal diseases that could be treated using gene-based medicines.